Zentalis Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share (ZNTL) Institutional Ownership

13F Institutional Holders and Ownership History from Q2 2020 to Q4 2025

Type / Class
Equity / Common Stock, $0.001 par value per share
Symbol
ZNTL on Nasdaq
Shares outstanding
68,578,543
Price per share
$2.96
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
40,517,310
Total reported value
$54,747,321
% of total 13F portfolios
0%
Share change
-12,787,621
Value change
-$20,006,113
Number of holders
83
Price from insider filings
$2.96
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Zentalis Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share (ZNTL) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
WALTERS GROUP 20% $20,264,960 13,509,973 Walters William T 31 Dec 2025
Walters William T 9.9% +8.9% $10,081,500 +$786,500 7,050,000 +8.5% Walters William T 29 Jan 2025
5AM Opportunities II (GP), LLC 6.4% $7,257,856 4,838,571 Andrew J. Schwab 18 Dec 2025
BARCLAYS PLC 5.3% $5,800,588 3,841,449 Barclays PLC 30 Sep 2025
VANGUARD GROUP INC 4.6% $4,677,873 3,271,240 The Vanguard Group 31 Dec 2024
BlackRock, Inc. 2.2% $1,952,121 1,613,323 BlackRock, Inc. 30 Jun 2025
MILLENNIUM MANAGEMENT LLC 1.3% -80% $1,272,555 -$4,059,076 902,521 -76% Millennium Management LLC 30 Sep 2025
FMR LLC 0.2% $251,484 175,863 FMR LLC 29 Nov 2024

As of 31 Dec 2025, 83 institutional investors reported holding 40,517,310 shares of Zentalis Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share (ZNTL). This represents 59% of the company’s total 68,578,543 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Zentalis Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share (ZNTL) together control 51% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
5AM Venture Management, LLC 5.8% 3,947,913 +706% 1.7% $5,329,683
RENAISSANCE TECHNOLOGIES LLC 4.2% 2,883,745 +24% 0.01% $3,893,056
VANGUARD GROUP INC 4.2% 2,855,590 -1.7% 0% $3,855,047
ACADIAN ASSET MANAGEMENT LLC 4.2% 2,849,294 +0.15% 0.01% $3,839,000
CITADEL ADVISORS LLC 2.9% 1,964,255 -5.4% 0% $2,651,744
D. E. Shaw & Co., Inc. 2.4% 1,660,378 +18% 0% $2,241,510
TWO SIGMA ADVISERS, LP 2.2% 1,483,500 +1.5% 0% $2,002,725
TWO SIGMA INVESTMENTS, LP 2.1% 1,471,414 +7.9% 0% $1,986,409
Opaleye Management Inc. 2% 1,400,906 +343% 0.25% $1,891,223
BANK OF AMERICA CORP /DE/ 2% 1,367,254 -12% 0% $1,845,793
Decheng Capital LLC 1.9% 1,323,327 0% 0.24% $1,786,491
Ishara Investments LP 1.9% 1,320,000 0% 2.1% $1,782,000
BlackRock, Inc. 1.8% 1,249,968 +0.04% 0% $1,687,457
GSA CAPITAL PARTNERS LLP 1.7% 1,169,573 +8.5% 0.14% $1,579,000
PRIMECAP MANAGEMENT CO/CA/ 1.4% 957,420 -0.54% 0% $1,292,517
Pfizer Inc 1.4% 953,834 0% 0.54% $1,287,675
MORGAN STANLEY 1.2% 803,654 -43% 0% $1,084,932
Connor, Clark & Lunn Investment Management Ltd. 1.1% 787,055 +107% 0% $1,062,524
UBS Group AG 0.98% 674,598 +27% 0% $910,707
MILLENNIUM MANAGEMENT LLC 0.98% 673,129 -25% 0% $908,724
Almitas Capital LLC 0.89% 610,073 +33% 0.18% $823,599
GEODE CAPITAL MANAGEMENT, LLC 0.86% 589,105 -0.02% 0% $795,720
XTX Topco Ltd 0.84% 576,707 +5.1% 0.02% $778,554
BARCLAYS PLC 0.83% 568,443 +252% 0% $767,398
Woodline Partners LP 0.77% 530,582 0% 0% $716,286

Institutional Holders of Zentalis Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share (ZNTL) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 40,517,310 $54,747,321 -$20,006,113 $1.35 83
2025 Q3 52,767,851 $79,681,182 -$3,987,959 $1.51 97
2025 Q2 55,655,238 $64,573,024 -$4,209,380 $1.16 115
2025 Q1 58,450,755 $92,928,558 -$20,527,901 $1.59 131
2024 Q4 64,418,043 $195,184,400 -$24,736,255 $3.03 141
2024 Q3 70,964,067 $261,154,970 -$21,635,153 $3.68 133
2024 Q2 76,565,937 $313,165,477 -$54,359,485 $4.09 142
2024 Q1 85,290,558 $1,344,227,610 +$67,005,140 $15.76 140
2023 Q4 81,068,438 $1,228,198,230 -$21,970,408 $15.15 118
2023 Q3 80,197,042 $1,608,751,464 -$51,643,382 $20.06 136
2023 Q2 82,228,758 $2,319,672,532 +$442,954,370 $28.21 131
2023 Q1 67,021,594 $1,152,767,927 +$44,945,526 $17.20 108
2022 Q4 64,360,813 $1,296,145,033 +$105,231,060 $20.14 106
2022 Q3 58,811,479 $1,273,846,102 -$54,003,564 $21.66 116
2022 Q2 58,254,677 $1,636,896,016 +$359,446,058 $28.10 115
2022 Q1 44,437,538 $2,050,628,439 +$49,057,461 $46.14 123
2021 Q4 42,987,158 $3,611,907,936 +$90,022,119 $84.06 134
2021 Q3 41,250,292 $2,749,252,645 +$115,288,600 $66.64 114
2021 Q2 39,699,603 $2,112,018,735 +$205,833,024 $53.20 117
2021 Q1 36,327,192 $1,576,156,109 -$55,960,381 $43.39 93
2020 Q4 37,299,066 $1,937,340,198 +$309,645,949 $51.94 104
2020 Q3 31,635,340 $1,033,195,545 +$169,604,096 $32.69 65
2020 Q2 26,858,048 $1,282,608,905 +$1,282,608,902 $48.02 61